+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sickle Cell Disease Treatment - Global Market Trajectory & Analytics

  • ID: 5309831
  • Report
  • April 2021
  • Region: Global
  • 182 pages
  • Global Industry Analysts, Inc
Global Sickle Cell Disease Treatment Market to Reach $589.5 Million by 2027

Amid the COVID-19 crisis, the global market for Sickle Cell Disease Treatment estimated at US$397.7 Million in the year 2020, is projected to reach a revised size of US$589.5 Million by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Hydroxyurea, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$244.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibiotics segment is readjusted to a revised 6.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $117.9 Million, While China is Forecast to Grow at 4.9% CAGR

The Sickle Cell Disease Treatment market in the U.S. is estimated at US$117.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.5 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Pain-Relieving Medications Segment to Record 5.7% CAGR

In the global Pain-Relieving Medications segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.8 Million in the year 2020 will reach a projected size of US$98.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$69.1 Million by the year 2027.

Select Competitors (Total 41 Featured):
  • Acceleron Pharma, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Emmaus Life Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sangamo Therapeutics, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Sickle Cell Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Sickle Cell Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Sickle Cell Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Hydroxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Hydroxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Hydroxyurea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Pain-Relieving Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Pain-Relieving Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Pain-Relieving Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Sickle Cell Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Sickle Hemoglobin C Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Sickle Hemoglobin C Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Sickle Hemoglobin C Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for Sickle Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Sickle Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for Sickle Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 25: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 26: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 28: USA Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: USA Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: USA 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 31: USA Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: USA Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: USA 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • CANADA
  • Table 34: Canada Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Canada Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Canada 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 37: Canada Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Canada Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Canada 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 40: Japan Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Japan Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Japan 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 43: Japan Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Japan Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Japan 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • CHINA
  • Table 46: China Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: China Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: China 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 49: China Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: China Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: China 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 52: Europe Current & Future Analysis for Sickle Cell Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Sickle Cell Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Sickle Cell Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 55: Europe Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Europe Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Europe 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 58: Europe Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Europe Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: Europe 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 61: France Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: France Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: France 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 64: France Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: France Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: France 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 67: Germany Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Germany Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: Germany 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 70: Germany Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: Germany Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: Germany 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • ITALY
  • Table 73: Italy Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: Italy Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: Italy 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 76: Italy Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: Italy Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: Italy 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 79: UK Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: UK Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: UK 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 82: UK Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: UK Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: UK 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 85: Rest of Europe Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of Europe Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of Europe 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 88: Rest of Europe Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of Europe Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of Europe 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 91: Asia-Pacific Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Asia-Pacific Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 93: Asia-Pacific 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 94: Asia-Pacific Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 95: Asia-Pacific Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 96: Asia-Pacific 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 97: Rest of World Current & Future Analysis for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 98: Rest of World Historic Review for Sickle Cell Disease Treatment by Drug Type - Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 99: Rest of World 15-Year Perspective for Sickle Cell Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Hydroxyurea, Antibiotics, Pain-Relieving Medications and Other Drug Types for the Years 2012, 2020 & 2027
  • Table 100: Rest of World Current & Future Analysis for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 101: Rest of World Historic Review for Sickle Cell Disease Treatment by Disease Type - Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 102: Rest of World 15-Year Perspective for Sickle Cell Disease Treatment by Disease Type - Percentage Breakdown of Value Sales for Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia and Other Disease Types for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll